Analyst Ratings For NASDAQ:VBIV – VBI Vaccines (NASDAQ:VBIV)
Today, BMO Capital Markets reiterated its Outperform rating on NASDAQ:VBIV – VBI Vaccines (NASDAQ:VBIV) with a price target of $11.00 ➝ $13.00.
Some recent analyst ratings include
- 5/10/2018-BMO Capital Markets Reiterated Rating of Outperform.
- 3/23/2018-Noble Financial Reiterated Rating of Buy.
- 11/1/2017-Canaccord Genuity initiated coverage with a Buy ➝ Buy rating.
- 10/10/2016-Laidlaw initiated coverage with a Buy rating.
- 7/26/2016-Ladenburg Thalmann initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:VBIV – VBI Vaccines (NASDAQ:VBIV)
NASDAQ:VBIV – VBI Vaccines (NASDAQ:VBIV) has insider ownership of 16.20% and institutional ownership of 48.47%.
- On 12/12/2017 Jeff Baxter, CEO, bought 10,000 with an average share price of $3.89 per share and the total transaction amounting to $38,900.00.
- On 11/28/2017 Jeff Baxter, CEO, bought 15,000 with an average share price of $4.75 per share and the total transaction amounting to $71,250.00.
- On 10/30/2017 Opko Health, Inc., Major Shareholder, bought 655,738 with an average share price of $3.05 per share and the total transaction amounting to $2,000,000.90.
- On 10/30/2017 Steven Gillis, Director, bought 300,000 with an average share price of $3.05 per share and the total transaction amounting to $915,000.00.
- On 10/26/2017 Life Sciences Maste Perceptive, Major Shareholder, bought 3,100,000 with an average share price of $3.05 per share and the total transaction amounting to $9,455,000.00.
- On 8/21/2017 Francisco Diaz-Mitoma, Insider, bought 3,000 with an average share price of $3.17 per share and the total transaction amounting to $9,510.00.
- On 8/21/2017 Jeff Baxter, CEO, bought 10,000 with an average share price of $3.22 per share and the total transaction amounting to $32,200.00.
Recent Trading Activity for NASDAQ:VBIV – VBI Vaccines (NASDAQ:VBIV)
Shares of NASDAQ:VBIV – VBI Vaccines closed the previous trading session at 3.14 up +0.21 7.31% with shares trading hands.